Back

Use of sacubitril valsartan in heart failure due to post-chemotherapy symptomatic ventricular dysfunction

29 May 2018 (08:00 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Chronic Heart Failure – Pathophysiology and Mechanisms Cardiotoxicity of Drugs and Other Therapies HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Vanesa Gregorietti

Sanatorio Sagrado Corazon, Buenos Aires (Argentina)

25 More presentations in this session

Presentation thumbnail
Professor M. Senni (Bergamo, IT)
Abstract
Presentation thumbnail
Presentation thumbnail
Doctor I. Alexanian (Athens, GR)
Presentation thumbnail
Doctor M. Feola (Mondovi, IT)
Abstract
Presentation thumbnail
Professor N. Lyamina (Moscow, RU)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Chronic Heart Failure – Pathophysiology and Mechanisms

The Event

Event poster

Heart Failure 2018

29 May 2018 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Sacubitril/Valsartan and cardiovascular outcomes in cancer patients on anthracycline therapy: a global health research network retrospective analysis
20 June 2025
thumbnail
Webinar
How to manage cancer therapy-related cardiovascular toxicity. ESC 2022 Clinical Practice Guidelines - Webinar Series
19 September 2022
thumbnail
Congress Presentation
Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction
22 May 2023
thumbnail
ESC Journals
Uprising heart failure therapies for cardio-permissive strategies in cancer therapy-related cardiac dysfunction
1 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources